NASDAQ:TCRX - Tscan Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $21.67
  • Forecasted Upside: 147.62 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$8.75
▲ +0.02 (0.23%)

This chart shows the closing price for TCRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Tscan Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRX

Analyst Price Target is $21.67
▲ +147.62% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Tscan Therapeutics in the last 3 months. The average price target is $21.67, with a high forecast of $22.00 and a low forecast of $21.00. The average price target represents a 147.62% upside from the last price of $8.75.

This chart shows the closing price for TCRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Tscan Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/26/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/13/2021CowenInitiated CoverageOutperformHigh
8/10/2021BarclaysInitiated CoverageOverweight$22.00High
8/10/2021Jefferies Financial GroupInitiated CoverageBuy$21.00High
8/10/2021Morgan StanleyInitiated CoverageOverweight$22.00High
(Data available from 11/27/2016 forward)

News Sentiment Rating

0.31 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/29/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Tscan Therapeutics logo
TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.
Read More

Today's Range

Now: $8.75
Low: $8.53
High: $8.98

50 Day Range

MA: $8.02
Low: $6.17
High: $9.05

52 Week Range

Now: $8.75
Low: $6.06
High: $14.71

Volume

4,465 shs

Average Volume

72,689 shs

Market Capitalization

$207.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Tscan Therapeutics?

The following sell-side analysts have issued reports on Tscan Therapeutics in the last twelve months: Barclays PLC, Cowen Inc, Jefferies Financial Group Inc., Morgan Stanley, and Zacks Investment Research.
View the latest analyst ratings for TCRX.

What is the current price target for Tscan Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Tscan Therapeutics in the last year. Their average twelve-month price target is $21.67, suggesting a possible upside of 147.6%. Barclays PLC has the highest price target set, predicting TCRX will reach $22.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $21.00 for Tscan Therapeutics in the next year.
View the latest price targets for TCRX.

What is the current consensus analyst rating for Tscan Therapeutics?

Tscan Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCRX will outperform the market and that investors should add to their positions of Tscan Therapeutics.
View the latest ratings for TCRX.

What other companies compete with Tscan Therapeutics?

How do I contact Tscan Therapeutics' investor relations team?

Tscan Therapeutics' physical mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for Tscan Therapeutics is www.tscan.com.